LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy
The Prostate · 2025
DOI: 10.1002/pros.24899 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Sangjon Pae und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Testosterone, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: This study was supported by a KAKENHI grant (23K19497), a Translational Research Grant of Urological Oncology, and a research grant from the Astellas Foundatio….
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Maintaining a castration level of testosterone (TST) during radiation therapy combined with androgen deprivation therapy (ADT) is an essential strategy in the treatment of prostate cancer; however, hypogonadism can cause various complications. The aim was to compare serum TST recovery between LHRH agonists and LHRH antagonists.
Methods
A total of 131 patients who underwent radiation therapy with ADT for prostate cancer were retrospectively analyzed. Serum TST levels after termination of ADT including LHRH agonists and antagonists were compared. Cox proportional hazards model and the Kaplan–Meier method were used for statistical analysis.
Results
Median age, baseline TST, nadir TST, and duration of ADT were 71 years, 535 ng/dL, 10.92 ng/dL, and 12 months, respectively. Multivariate analysis identified significant associations of initial PSA ≥ 10.92 ng/mL ( p = 0.0366), ADT ≥ 360 days ( p = 0.0408), nadir TST ≤ 19 ng/dL ( p = 0.0003), and LHRH agonist ( p = 0.0027) with delayed TST recovery to castration level (50 ng/dL). We created a risk model based on these four independent risk factors (Low: 0–1 factor/Intermediate: 2 factors/High Risk: 3–4 factors). Each risk group significantly differentiated the TST recovery to castration level. Even after propensity score matching, recovery of TST to castration level and therapeutic level (200 ng/dL) was significantly delayed in the LHRH agonist group compared with the LHRH antagonist group ( p = 0.0016, p = 0.0389, respectively).
Conclusion
LHRH antagonists restored serum TST to castration and therapeutic levels faster than LHRH agonists in prostate cancer patients undergoing radiation therapy with ADT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Urology, Matsudo City General Hospital, Chiba, Japan.
- Department of Urology, JCHO Mishima General Hospital, Shizuoka, Japan.
ORCID-Profile: Sangjon Pae, Shinichi Sakamoto
Förderung
- This study was supported by a KAKENHI grant (23K19497), a Translational Research Grant of Urological Oncology, and a research grant from the Astellas Foundatio…
Zitieren
APA
Pae, S., Sakamoto, S., Zhao, X., Tamura, T., Kamasako, T., Takei, A., Yamada, Y., Sazuka, T., Imamura, Y., Akakura, K., & Ichikawa, T. (2025). LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy. The Prostate. https://doi.org/10.1002/pros.24899
Vancouver
Pae S, Sakamoto S, Zhao X, Tamura T, Kamasako T, Takei A, et al. LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy. The Prostate. 2025. doi:10.1002/pros.24899
BibTeX
@article{Pae2025,
author = {Pae, Sangjon and Sakamoto, Shinichi and Zhao, Xue and Tamura, Takaaki and Kamasako, Tomohiko and Takei, Akinori and Yamada, Yasutaka and Sazuka, Tomokazu and Imamura, Yusuke and Akakura, Koichiro and Ichikawa, Tomohiko},
title = {LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24899}
}
EUVIMED